Tuberculosis is a serious opportunistic infection in transplant recipients. On the basis of the compilation of published reports in the literature, the incidence of Mycobacterium tuberculosis infection in organ transplant recipients worldwide ranged from 0.35% to 15%. Nonrenal transplantation (P Å .004), rejection within 6 months before the onset of tuberculosis (P Å .02) and type of primary immunosuppressive regimen (P Å .007) were predictors of M. tuberculosis infection occurring within 12 months after transplantation. Thirty-three percent (155) of 476 transplant patients with tuberculosis had disseminated infection; receipt of OKT3 or anti -T cell antibodies (P Å .005) was a significant predictor of disseminated tuberculosis. Overall, the mortality rate among 499 patients was 29%; disseminated infection (P Å .0003), prior rejection (P Å .006), and receipt of OKT3 or anti -T cell antibodies (P Å .0013) were significant predictors of mortality in patients with tuberculosis. Clinically significant hepatotoxicity due to isoniazid occurred in 2.5%, 4.5%, and 41% of renal, heart and lung, and liver transplant recipients, respectively. The diagnosis and effective management of tuberculosis after transplantation warrant recognition of the unique epidemiological and clinical characteristics of tuberculosis in transplant recipients.
Tuberculosis is a significant opportunistic infection in transcases or series with small sample sizes [5, 14, 23, 24] . Nevertheless, concerns about hepatotoxicity due to isoniazid have plant recipients worldwide. Whereas the frequency of Mycobacterium tuberculosis infection in most developing countries rendered prophylaxis a complex and controversial issue for transplant recipients. ranges from 1.2% to 6.4% [1 -8] , up to 15% of transplant recipients in areas of high-level endemicity may develop tuber-
The existing literature on M. tuberculosis infection after transplantation is largely made up of institutional experiences culosis [5] . Although tuberculosis is documented less frequently in transplant centers in North America, the incidence with a few patients or case reports. Given the small number of transplant recipients with tuberculosis who are encountered of tuberculosis among transplant recipients (even those in the United States) is 36-to 74-fold higher than that among the at individual institutions, a prospective study addressing aforementioned and other relevant issues appears largely unfeasible. general population [9 -12] .
Regardless of the geographic variation in the incidence, tuHowever, an adequate cumulation and synthesis of existing studies could yield valuable data regarding the overall impact berculosis remains one of the most serious bacterial infections after transplantation. Tuberculosis in transplant recipients, even and management of tuberculosis in transplant recipients. This review addresses and summarizes the unique epidemiological in the 1990s, is associated with mortality rates ranging from 25% to 40% [12 -15] . Furthermore, it is often not appreciated features of M. tuberculosis infection after transplantation; diverse clinical sequelae; identifiable risk factors; diagnosis; efthat allograft loss due to rejection may ensue in up to 33% of transplant patients receiving antituberculosis therapy [13, 16] .
ficacy and adverse consequences of chemoprophylaxis; variables influencing outcome; and differences in epidemiology, M. tuberculosis infection after transplantation often defies early recognition and timely diagnosis, since extrapulmonary disease presentation, risk of isoniazid hepatotoxicity, and outcome for different types of solid organ transplant recipients. occurs frequently [3, 17 -22] . The management of tuberculosis in this setting is equally challenging because of the side effects of antituberculous agents and their potential interactions with Methods immunosuppressive drugs. Opinions on the approach to chemoprophylaxis are based largely on observations from individual Previously described M. tuberculosis infections in transplant recipients from 1967 through 1997 were identified via a MED-LINE search by cross-referencing the keywords tuberculosis and transplantation or transplant. Additional cases were identi-infections could not be made or in which the precise criteria for the diagnosis of tuberculosis could not be discerned were Of 511 cases of tuberculosis, 437, 44, 17, and 13 occurred not included. Finally, the reports were limited to those pubin renal, liver, heart, and lung (heart and lung, 5; double lung, lished in or translated into English. Cases reported in more 4; and single lung, 4) transplant recipients, respectively. Of than one report from a single institution were considered only 239 renal transplant recipients, 51% (122) received a cadaveric once.
allograft, 44% (106) received a living-related allograft, and 5% A patient was considered to have tuberculosis if M. tubercu-(11) received a living-unrelated allograft. To our knowledge, losis was detected in a culture of any clinical specimen, body thus far no cases of tuberculosis have been described in bowel fluid, or tissue specimen or if acid-fast bacilli or caseating or pancreatic transplant recipients. The incidence of tuberculogranulomas were documented along with a clinical response sis in transplant recipients worldwide ranged from 0.35% to to antituberculous therapy specifically directed against M. tu-15%. The incidence among renal transplant recipients was berculosis [13] . Cases of fever of unknown origin or pulmonary 0.35% to 1.2% in the United States, 0.7% to 5% in Europe, infection suspected of being due to tuberculosis but in which 1.5% to 3.5% in the Middle East, 1.5% to 8.2% in South Africa, a definitive diagnosis of M. tuberculosis infection was either 3.1% to 5% in Southeast Asia, and 5% to 15% in India and not pursued or not documented were not included.
Pakistan. M. tuberculosis infections in nonrenal transplant reTuberculosis was considered to be disseminated when culcipients have been described almost exclusively in Europe and tures of specimens from two or more noncontiguous organ sites the United States; the frequency of tuberculosis ranged from were positive for M. tuberculosis or if acid-fast bacilli and/or 1% to 1.4%, 0.9% to 2.3%, and 2% to 6.5% among heart, liver, granulomas were detected in specimens from one or more organ and lung transplant recipients, respectively [11, 12, 14, 25 , 36 -sites in a patient for whom culture of a specimen from a non-38, 64, 65, 67, 70, 93, 97] . contiguous site was positive for M. tuberculosis [13] . Determi-
The patients' ages ranged from 10 months to 71 years (mean, nation of the time of onset was based on individually detailed 39 years); various types of solid organ transplant recipients did case studies; summarized data where only a mean or range for not differ significantly from each other with respect to age. the group of transplant recipients was provided were excluded Sixty-six percent of the patients were male. In two (7%) of 29 from this analysis. For the assessment of predictors or risk liver transplant recipients and in six (4%) of 135 renal transfactors for a particular end point (e.g., mortality, disseminated plant recipients, tuberculosis occurred after retransplantation; disease, etc.), only individually detailed cases where the varinone of the heart or lung transplant patients with tuberculosis ables to be analyzed were explicitly stated were included. Morunderwent retransplantation. Of the 511 transplant recipients, tality was considered attributable to tuberculosis if M. tubercuonly 0.4% (two) were HIV-positive [13, 14] ; these patients losis infection was documented at autopsy or if there was included one liver transplant recipient known to have HIV evidence of active tuberculosis at the time of death and no infection before transplantation and one renal transplant recipiother etiology accounted for death. ent in whom HIV infection was inadvertently acquired from Statistical analysis. Patient demographics were entered the donor [13] . into the database PROPHET Statistics Version 5.0 (BBN SysFor 410 transplant recipients, the primary immunosuppressive tems and Technologies, Cambridge, MA). The x 2 or Fisher's regimen was cyclosporine and azathioprine in 47% (193), azathioexact test was used to compare categorical variables (e.g., presprine in 37% (151), cyclosporine in 13% (54) , and tacrolimus in ence or absence of an underlying condition). Continuous vari-3% (12) . Overall, 20 (10%) of 207 patients had received OKT3 ables (e.g., time of onset, etc.) were compared by using the t or anti-T cell antibodies, including 5 (25%) of 20 liver transplant test or the Mann-Whitney U test. Multiple comparisons were recipients, 2 (20%) of 10 lung recipients, and 13 (7%) of 177 renal done by using analysis of variance and the Kruskal-Wallis test.
transplant recipients. The mean dose of prednisone for patients for The time of onset of tuberculosis relative to transplantation whom this information was stated was 20 mg, 5 mg, and 2.5 mg was examined by using a Kaplan-Meier probability plot; the for the renal, heart, and liver transplant recipients, respectively. two Kaplan-Meier curves were compared by using the MantelFifty percent (70) of 139 transplant recipients had experienced Cox test. allograft rejection at any time preceding tuberculosis; rejection episodes had occurred within 6 months of the onset of tuberculosis in 38% (53) of 139 patients.
Results
A total of 511 cases of tuberculosis in solid organ transplant
Time of Onset
recipients were identified and reviewed [1 -109] . Of these 511 cases, 210 were individually detailed, and 301 were summaTuberculosis occurred a median of 9 months (range, 0.5 to 144 months) after transplantation (table 1). Tuberculosis rized in reports containing from two to 51 cases. Only 13% of the studies reported 10 or more cases. occurred significantly later in renal transplant recipients than (20) 28 (14) 34 (17) 12 (6) in other organ transplant recipients; the median time to onset Pretransplant chest radiographs of 12% (25) of 207 patients revealed evidence of old active tuberculosis; the proportion of after transplantation was 11.5 months, 4 months, 4 months, and 3.5 months for renal, liver, heart, and lung transplant recipients, patients whose chest roentgenograms demonstrated abnormalities did not differ significantly between the various types of respectively (P Å .004). Overall, 57% (86) [30] . One of the recipients of a renal allograft from this donor died of disseminated tuberculosis, whereas regimen (P Å .007). Forty-six percent (11) of 24 patients receiving cyclosporine alone, 53% (34) of 64 patients receiving the second recipient recovered (although rejection secondazathioprine alone, 68% (42) of 62 patients receiving cyclosporine plus azathioprine, and 100% (11) of 11 patients receiving tacrolimus alone developed tuberculosis within 1 year of transplantation (P Å .007).
By means of a Kaplan-Meier probability plot (figure 1), patients with a history of exposure to M. tuberculosis (a positive tuberculin skin test or radiographic evidence of old active tuberculosis) developed tuberculosis earlier than did those without a history of exposure, although this difference was not statistically significant (P Å .08; Mantel-Cox test). Seventy-nine percent (15) of 19 evaluable patients who had received OKT3 or anti -T cell antibodies developed tuberculosis within 12 months of transplantation compared with 64% (63) of 99 who had not received OKT3 or anti -T cell antibodies (P Å .19). Age, rejection occurring ú6 months before the onset of tuberculosis, and country of origin were not significant predictors of earlyvs. late-onset tuberculosis. the most frequent modes of acquisition of tuberculosis. CID 1998;27 (November)
M. tuberculosis Infection in Transplant Recipients
Clinical Manifestations ary to antituberculosis therapy necessitated allograft nephrectomy) [30] . The same M. tuberculosis isolates were Of 476 patients, 51% (244) had pulmonary tuberculosis, recovered from two recipients of a single-lung transplant 16% (77) had extrapulmonary tuberculosis, and 33% (155) had from a common donor; restriction fragment length polymordisseminated tuberculosis. Disseminated tuberculosis occurred phism analysis demonstrated that the isolates were the same in 48% (14) of 29 liver transplant recipients, 38% (5) of 13 [84] . Disseminated tuberculosis was also found in two reciplung transplant recipients, 40% (61) of 152 renal transplant ients of kidney allografts from the same donor [42] . Neither recipients, 36% (4) of 11 heart transplant recipients, and 25% of the two recipients had a history of active tuberculosis or (13) of 51 solid organ transplant recipients in a mixed group; tuberculin reactivity before transplantation [42] .
the difference in the frequency of disseminated disease between Donor transmission was considered highly probable for various organ transplant recipients was not statistically signifia pediatric recipient of a living-related lateral-segment hecant (table 2) . Disseminated infection was documented in 49% patic transplant; the sole site of M. tuberculosis infection (27) of 55 transplant recipients from the United States, 50% in this patient was a tuberculous abscess in the hepatic allo-(34) of 68 transplant recipients from Europe, and 28% (20) of graft [35] . Pulmonary (right upper lobe) tuberculosis was 71 transplant recipients from all other regions of the world detected concomitantly in this patient's mother who had (P Å .01). This finding is likely due to the fact that nonrenal donated the segmental hepatic allograft [35] . For two renal solid organ transplant recipients with tuberculosis in this report transplant recipients, donor transmission was considered (in whom cumulative immunosuppression may be greater) were likely in light of positive tuberculin skin tests documented almost exclusively from the United States and Europe. Patients for both donors of living-related renal allografts and negawith disseminated infection were also more likely to have retive tuberculin skin tests without prior evidence of tubercuceived OKT3 (P Å .005) than were patients without disseminlosis for the recipients [9, 56] . Donor transmission was also ated tuberculosis (table 2) . Age, type of organ transplant, type implicated for two bilateral-lung transplant recipients in of primary immunosuppressive regimen, rejection, and history whom M. tuberculosis infection was found only in the alloof exposure to tuberculosis were not significant predictors of grafts [11] . disseminated tuberculosis (table 2) . Fifteen cases were diagData on tuberculin skin testing were considered evaluable if nosed only at autopsy. the administration of the tuberculin skin test (whether performed)
Fever was a common occurrence in organ transplant recipiand the results were explicitly documented in the report; data ents with tuberculosis. Fever was significantly more likely to for 209 patients were evaluable in this analysis. Before transoccur in patients with disseminated infection than in those with plantation, only 47% (98) (20) of 32 patients with extraliver transplant recipients, 15% (8) of 52 renal transplant recipipulmonary tuberculosis had fever (P Å .0001). Constitutional ents, and none of three heart or two lung transplant recipients symptoms (e.g., night sweats and weight loss) were also frewho underwent tuberculin skin testing. Of 30 solid organ transquently observed. The leukocyte count was documented for 26 plant recipients, 20% (six) were PPD-positive [13] .
patients; only 35% (nine) of these 26 patients had leukopenia. A nosocomial outbreak of tuberculosis that involved 10 renal Pulmonary tuberculosis. The lung was the most frequently transplant patients was documented from one institution; eight involved site of tuberculosis (71% [336] of 476 patients). Fiftyof the 10 cases were clustered within a 5-month period [52] .
one percent (244) of 476 patients had pulmonary involvement The source case occurred in a renal transplant recipient who only, whereas 19% (92) of 476 patients had pulmonary involvewas exposed to tuberculosis at another hospital. Tuberculosis ment as part of disseminated tuberculosis. was not suspected in the source patient at the time of admission, The radiographic appearance of the pulmonary infiltrate(s) thus delaying isolation precautions. Restriction fragment length in 226 patients was a focal infiltrate in 40% (90), a miliary polymorphism analysis documented transmission of the donor pattern in 22% (49), nodules in 15% (35) , pleural effusions in M. tuberculosis strain to five renal transplant recipients. It is 13% (30), diffuse interstitial infiltrates in 5% (12) , and cavitary notable that the median incubation period for tuberculosis in this lung disease in 4% (8) . Forty-six percent (13) of 28 nonrenal outbreak was only 7.5 weeks, and death occurred in five of 10 transplant recipients compared with 14% (22) of 156 renal patients a median of 8 weeks after diagnosis.
transplant recipients had nodular infiltrates due to tuberculosis. Of 243 patients for whom a history of exposure to tuberculoThe frequency of other radiographic patterns of tuberculosis sis was sought, 3% (eight) had had contact with a family memdid not differ between various organ transplant recipients. ber with tuberculosis either before or after transplantation [4, Gastrointestinal tuberculosis. Gastrointestinal tract involve-13, 28, 65, 67, 91] . None of these patients received chemoprophylaxis for tuberculosis. ment was documented in 32 cases. Although the gastrointestinal The sites involved included the mediastinum in 5 patients, the seven patients with hepatitis, a patient with elevated liver enzyme levels (who did not undergo biopsy), and three of 12 cervical area in 5 (one of whom also had abdominal lymphadenopathy), the submandibular area in 1, the axillary area in 1, liver transplant recipients described in a group report [13, 14] . Thus, hepatotoxicity requiring discontinuation of isoniazid and an unspecified area in 6. In one case of fever of unknown origin, tuberculosis was serendipitously diagnosed when examtherapy occurred in 41% (11) of 27 liver transplant recipients. Hepatotoxicity was documented for one (10%) of 10 heart ination of a lymph node removed during parathyroidectomy revealed M. tuberculosis [17] . In all but three cases (two in transplant recipients [38] who received therapy with isoniazid, rifampin, and pyrazinamide; none of 12 lung transplant recipimediastinal areas and one in an unspecified site), lymphadenitis was part of disseminated tuberculosis. ents had hepatotoxicity.
Chemoprophylaxis. Although the efficacy of isoniazid proOther sites of M. tuberculosis infection included the pericardium, spleen, larynx, tonsil, and ocular choroid [3, 5, 15, 17, phylaxis has not been demonstrated in a controlled trial to our knowledge, case series and reports suggest that chemoprophy-18, 32, 33, 46, 49, 58, 67, 94] . Only eight cases of bone marrow involvement were documented. Adrenal involvement was demlaxis is effective for high-risk transplant recipients. A doubleblind, randomized, controlled trial of primary isoniazid prophyonstrated in only one case (a heart transplant recipient) at autopsy [66] .
laxis for dialysis and renal transplant recipients demonstrated a trend toward a lower incidence of tuberculosis in isoniazid recipients [54] . The study, however, lacked sufficient power; nearly one-half of the study patients had underlying hepatitis
Antituberculous Therapy
B virus infection, and administration of isoniazid and placebo was discontinued because of hepatitis in over one-third of the Overall, 83% (120) of 145 patients received isoniazid plus rifampin as part of antituberculous therapy for at least 6 months. patients in both treatment groups. Localized (120) 24 (20) 96 (80) (three) developed clinically significant hepatotoxicity [34] .
Pulmonary only (84) 16 ( (67) 26 (39) 41 (61) .006
hepatotoxicity [27] .
No (68) 12 (18) 56 (82) Rejection within 6 mo before tuberculosis
Mortality
Yes (52) 20 (38) 32 (62) .025 No (82) 17 (21) 65 (69) Overall, the mortality rate among organ transplant recipients
Receipt of OKT3 or anti -T with tuberculosis was 29% (146 of 499). The mortality rate cell antibodies was 30% (120 of 397), 21% (6 of 28), 18% (2 of 11), and
Yes (20) 12 (60) 8 (40) .0013
17% (2 of 12) among renal, liver, heart, and lung transplant
No (100) 24 (24) 76 (76) recipients, respectively, and 31% (16 of 51) among a mixed
Primary immunosuppressive regimen group [13] of solid organ transplant recipients. In 57% (68) of
Cyclosporine (23) 7 (30) 16 (70) NS 119 renal transplant recipients, 83% (five) of six liver transplant
Azathioprine (66) 25 (38) 41 (62) recipients, and all heart and lung transplant recipients with Cyclosporine plus tuberculosis who died, mortality was attributable to M. tubercuazathioprine (51) 11 (22) 40 (78) losis infection.
Tacrolimus (12) 4 (30) 8 ( (81) 17 (21) 64 (79) (70) 19 (27) 51 (73) The mortality rate was 38% among patients from the United States, 28% among those from Europe, and 27% among those antibodies compared with no receipt of OKT3 or anti -T cell antibodies (60% [12 of 20] vs. 24% [24 of 100], respectively; P Å .0013) were significant predictors of mortality in transplant recipients with tuberculosis (table 3) . 12 months of transplantation. The time between transplantation and the onset of tuberculosis was significantly longer for renal transplant recipients than for other organ transplant recipients.
Discussion
Renal transplant recipients are generally less immunosuppressed than liver, heart, or lung transplant recipients, which This review illustrates the characteristics and problems unique to transplant recipients with tuberculosis; to our knowlcould have accounted for the later occurrence of tuberculosis in renal transplant recipients. On the other hand, renal transedge, it represents the only exhaustive and systematic analysis of tuberculosis in a large number of transplant recipients. Tuplantation has been in existence longer than other organ transplantations. Thus, later occurrence of tuberculosis in renal berculosis occurred in 0.35% to 15% of the transplant recipients worldwide; this incidence was eightfold to 100-fold higher than transplant recipients may merely be reflective of longer followup of these patients. that among the general population in the respective countries [3, 7, 9 -11, 13, 22, 38] . The median time to onset was 9
Tuberculosis in organ transplant recipients may develop after reactivation of old quiescent disease, nosocomial expomonths after transplantation; 63% of the cases occurred within / 9c5b$$no35
10-14- Twenty-nine percent of 499 patients who developed tuberculosis died. Disseminated tuberculosis, prior rejection, and rewho received lung allografts from the same donor [84] . In two recipients, tuberculosis involved renal allografts that ceipt of OKT3 or anti -T cell antibodies for rejection were significant predictors of death in transplant recipients with tuwere from the same donor who died of tuberculous meningitis; in one of the two recipients, the renal allograft was the berculosis. Perhaps equally worrisome was the significant morbidity associated with tuberculosis in the patients who survived. only site of M. tuberculosis infection [30] .
DNA fingerprinting has also demonstrated the potential for Accelerated metabolism of immunosuppressive drugs and corticosteroids by rifampin may trigger allograft rejection [112] . nosocomial transmission and the unique vulnerability of transplant recipients to tuberculosis. During an institutional outbreak A reduction in corticosteroid levels, albeit to a lesser degree, can also occur with isoniazid therapy [3] . Graft loss was obof tuberculosis, five of 10 renal transplant recipients died a median of 8 weeks after onset, and graft loss occurred in an served in 27% (41) of 150 renal transplant recipients with tuberculosis and was attributable to chronic rejection in most additional patient after discontinuation of immunosuppressive therapy [52] ; it is noteworthy that transplant recipients exposed of these patients. Although simultaneous use of cyclosporine and rifampin has been accomplished by increasing the to tuberculosis were more likely to contract tuberculosis than were other nontransplant contacts of the source patient. The cyclosporine dose three-to fivefold (with the frequency of administration increased from twice to thrice daily) and by potential for nosocomial transmission in susceptible individuals can also create difficult and expensive logistic problems [110] .
doubling the dose of corticosteroids [47] , other investigators have found it virtually impossible to continue administration At the renal unit of a London hospital, 524 close contacts (61 of whom were renal transplant recipients) of a source patient of the combination of cyclosporine and rifampin [38, 67] . In one study, patients developing acute rejection as a consefor whom a smear was positive were screened at an estimated cost of £25,000 [110] .
quence of drug interactions were significantly more likely to die than were those who did not develop acute rejection [13] . Thus, Most tuberculous infections in transplant recipients, however, represent reactivation of old dormant disease. Notably, use of rifampin must be undertaken with extreme caution and with frequent monitoring of immunosuppressive drug levels. Emthe trend toward earlier development of tuberculosis after transplantation was stronger for patients with a history of exposure ployment of isoniazid-containing regimens, without inclusion of rifampin, is a valid alternative since the use of such regimens was (i.e., those with radiographic evidence of old active tuberculosis and those with a positive tuberculin skin test) than for those associated with outcomes comparable with those associated with regimens that included rifampin. Regimens not including rifampin without such a history (figure 1).
It is notable that nearly one-half of the transplant recipients should, however, be continued for 12-18 months. Despite limited data on isoniazid hepatotoxicity in transplant with tuberculosis had pulmonary tuberculosis and that onethird had disseminated tuberculosis. Receipt of OKT3 was a recipients, it is widely perceived that these patients are at increased risk of isoniazid-associated hepatotoxicity. Transiently predictor of disseminated tuberculosis. Age, type of organ transplant, type of primary immunosuppressive regimen, rejecelevated liver enzyme levels have been described in 9% -18% of patients in the general population who receive isoniazid tion, and history of exposure, on the other hand, did not increase the likelihood of disseminated disease. Fever was a near-unitherapy [113 -115] , with a rate of clinically significant hepatotoxicity of 6.8% [115] . Clinically significant hepatotoxicity deversal occurrence in transplant recipients with disseminated tuberculosis. Indeed, the number of patients with disseminated veloped in 2.5% (three) of 119 renal transplant recipients receiving azathioprine therapy [34] . It should be noted that tuberculosis and fever was significantly higher than the number of patients with localized tuberculosis and fever (91% vs. 64%, isoniazid in this study was employed for all renal transplant recipients (irrespective of the results of tuberculin skin testing respectively; P Å .0001).
Diverse and often unsuspected sites of tuberculous infection or other risk factors) for an indefinite period after transplantation; 15% of the patients had hepatitis B infection, and the that defied recognition in transplant recipients were illustrated in a number of reports. Gastrointestinal disease represented one patients' status of antibody to hepatitis C virus was unknown. Although preexistent chronic active hepatitis B infection does of the most elusive and the most commonly involved site of extrapulmonary disease in transplant recipients. Fever and not appear to increase the risk of hepatotoxicity, it may render determination of the etiology of hepatic dysfunction in transvarying severity of gastrointestinal bleeding (ranging from heme-positive stools to massive bleeding) were the usual preplant recipients problematic. In a study of primary isoniazid prophylaxis in an area where senting symptoms [20, 22, 32, 49, 50, 96, 108] . Whereas ileocecal, clonic, or pancreatic tuberculosis often presented as localtuberculosis was endemic and 50% of the patients had hepatitis / 9c5b$$no35 10-14-98 12:22:57 cidas UC: CID die, and in an equal number of patients, allograft rejection or graft loss may ensue. The potential for transmission of undiagnosed tuberculosis, particularly in the nosocomial setting, may lead to life-threatening sequelae and costly investigations. Al-B infection, 36% of the placebo-treated patients and 35% of though tuberculosis is treatable when promptly diagnosed, unthe isoniazid-treated patients required discontinuation of the usual manifestations often defy timely recognition, and many respective therapy because of clinically diagnosed hepatitis cases are diagnosed only at autopsy. Furthermore, the risk of [54] . More recently, in a study of 83 renal transplant recipients isoniazid hepatotoxicity, particularly in nonliver transplant rereceiving cyclosporine therapy, isoniazid chemoprophylaxis cipients, does not appear to be higher for transplant recipients was employed for a mean of 344 days after transplantation than for the general population. Thus, chemoprophylaxis for [27] . None of the patients developed clinical hepatotoxicity or all identifiable high-risk patients is recommended (table 4) . required discontinuation of isoniazid therapy. Ten percent of Recipients of OKT3 who belong to any of the above-menthe patients had mildly elevated transaminase levels before tioned high-risk categories (including those who have only isoniazid therapy was started. During chemoprophylaxis, 31% tuberculin reactivity) must receive prophylaxis, since these paof the patients had mild self-limited elevations in transaminase tients are at significant risk not only for disseminated disease levels, usually within 10 days of initiation of therapy, that but also for death if tuberculosis develops. Currently, however, decreased without the need for discontinuation of isoniazid routine use of isoniazid prophylaxis cannot be recommended therapy.
for anergic transplant recipients who do not belong to the aforeOur data show that clinically significant hepatotoxicity rementioned high-risk categories. quiring discontinuation of isoniazid therapy occurred in 2.5%, Although limited by bias inherent to any retrospective study, 4.5%, and 41% of renal, heart and lung, and liver transplant this review summarizes the overall impact of M. tuberculosis recipients, respectively. Although liver transplant recipients apinfection in solid organ transplant recipients and highlights key peared to be more vulnerable to isoniazid-associated hepatotoxfeatures -many of which were previously poorly defined or icity, it should be noted that liver biopsies of liver transplant perhaps even unappreciated -that are based on case series recipients receiving antituberculous therapy were as likely to only. Most M. tuberculosis infections, particularly in nonrenal show rejection and/or hepatic tuberculosis as isoniazid hepatotransplant recipients, occur within the first 12 months of transtoxicity. Indeed, eight of 15 liver biopsies demonstrated acute plantation, and definable variables (portending poor outcome or chronic rejection plus granulomas (six) or only granulomas and risk of dissemination) exist. Chemoprophylaxis for identi-(two) in patients receiving isoniazid-containing regimens.
fiable high-risk patients is desirable and feasible. Therefore, these data suggest that a presumptive diagnosis of isoniazid hepatotoxicity may not be accurate for liver transplant
